| abstract |
A compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in a method of treating metastatic castration resistant prostate cancer, non-metastatic castration resistant prostate cancer, castration sensitive prostate cancer metastatic, non-metastatic castration-sensitive prostate cancer or high-risk localized prostate cancer in a male human patient, comprising orally administering the compound of Formula (I), or a pharmaceutically acceptable salt thereof, ** (See formula ) ** to a male human patient in need of such treatment at a dose of from about 30 mg per day to about 480 mg per day, in combination with abiraterone acetate and prednisone. |